Your session is about to expire
← Back to Search
COVAC-2 for COVID-19
Study Summary
This trial is testing a new vaccine called COVAC-2, which contains a portion of the SARS-CoV-2 spike protein. The purpose of the study is to see if the vaccine is safe and effective in preventing severe COVID-19 illness. The study will involve two groups of people, one group receiving the vaccine and the other receiving a placebo. The study will also include an open-label exploratory study arm to evaluate safety and immunogenicity of a single COVAC-2 dose in previously SARS-CoV-2-infected individuals.
- Double Vaccinated for COVID-19
- COVID-19
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have an autoimmune disease.You have a bleeding disorder or have experienced significant bleeding or bruising after getting shots or having blood drawn before.You have taken any experimental medication in the last 6 months.You have received blood products or immunoglobulin (IVIg or IMIg) within the last 3 months before the study.You have had a bad reaction or allergy to any part of the study vaccine in the past.
- Group 1: COVAC-2 10 µg group
- Group 2: COVAC-2 25 µg group
- Group 3: Placebo Control
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment accepting new participants?
"The information on clinicialtrials.gov indicates that this trial is actively recruiting participants. The initial posting date was July 22nd 2022 and the most recent update happened on August 24th 2022."
What is the size of this clinical trial's participant population?
"Affirmative. The official records on clinicaltrials.gov indicate that the trial, which opened for recruitment in July of 2022, is still recruiting participants from 3 sites with a total enrolment target of 380 individuals."
Share this study with friends
Copy Link
Messenger